Compare Stocks: ANL, RLAY, CELC, and TLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.75 -5.1%	$13.89	$0.88 ▼ $17.25	$1.07B	1.04	164,403 shs	218,130 shs
CELC Celcuity	$79.99 -4.9%	$89.02	$44.42 ▼ $151.02	$4.12B	0.19	798,986 shs	739,309 shs
RLAY Relay Therapeutics	$18.03 -6.8%	$19.26	$4.32 ▼ $21.27	$4.24B	1.69	3.29 million shs	4.71 million shs
TLX Telix Pharmaceuticals	$11.27 -5.7%	$11.32	$6.28 ▼ $13.11	$4.06B	-0.17	359,219 shs	462,721 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	-5.12%	+1.48%	+11.23%	+55.02%	+779.89%
CELC Celcuity	-4.89%	-3.14%	-11.90%	-16.62%	+52.36%
RLAY Relay Therapeutics	-6.82%	-4.30%	-8.76%	+1.12%	+305.17%
TLX Telix Pharmaceuticals	-5.69%	-4.73%	-3.51%	+3.78%	+3.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.75 -5.1%	$13.89	$0.88 ▼ $17.25	$1.07B	1.04	164,403 shs	218,130 shs
CELC Celcuity	$79.99 -4.9%	$89.02	$44.42 ▼ $151.02	$4.12B	0.19	798,986 shs	739,309 shs
RLAY Relay Therapeutics	$18.03 -6.8%	$19.26	$4.32 ▼ $21.27	$4.24B	1.69	3.29 million shs	4.71 million shs
TLX Telix Pharmaceuticals	$11.27 -5.7%	$11.32	$6.28 ▼ $13.11	$4.06B	-0.17	359,219 shs	462,721 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	-5.12%	+1.48%	+11.23%	+55.02%	+779.89%
CELC Celcuity	-4.89%	-3.14%	-11.90%	-16.62%	+52.36%
RLAY Relay Therapeutics	-6.82%	-4.30%	-8.76%	+1.12%	+305.17%
TLX Telix Pharmaceuticals	-5.69%	-4.73%	-3.51%	+3.78%	+3.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.71	Moderate Buy	$29.50	87.30% Upside
CELC Celcuity	2.83	Moderate Buy	$154.75	93.46% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	43.74% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$20.50	81.90% Upside

Current Analyst Ratings Breakdown

Latest ANL, RLAY, CELC, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/21/2026	TLX Telix Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
9/17/2026	CELC Celcuity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$157.00
9/15/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/14/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	202.86	N/A	N/A	($0.21) per share	-75.00
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
RLAY Relay Therapeutics	$15.35M	257.40	N/A	N/A	$3.27 per share	5.51
TLX Telix Pharmaceuticals	$803.79M	4.76	$0.04 per share	283.42	$1.23 per share	9.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	86.69	N/A	N/A	N/A	N/A	N/A

Latest ANL, RLAY, CELC, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	0.65
CELC Celcuity	6.04	8.93	8.93
RLAY Relay Therapeutics	N/A	18.27	18.27
TLX Telix Pharmaceuticals	1.16	2.01	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
CELC Celcuity	63.33%
RLAY Relay Therapeutics	96.98%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
CELC Celcuity	13.33%
RLAY Relay Therapeutics	5.04%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A

ANL, RLAY, CELC, and TLX Headlines

Recent News About These Companies

Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus

3 hours ago | finance.yahoo.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

September 23 at 11:59 AM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush

September 23 at 8:23 AM | marketbeat.com

What could Telix Pharmaceuticals (ASX:TLX) mean for Healthcare Stocks?

September 23 at 1:55 AM | kalkinemedia.comK

Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach

September 23 at 1:55 AM | finance.yahoo.com

Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply

September 22 at 7:11 PM | insidermonkey.com

Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript

September 22 at 7:00 PM | seekingalpha.com

Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day - Slideshow

September 22 at 4:42 PM | seekingalpha.com

Herbert Smith Freehills Kramer advises Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies Munich SE

September 22 at 10:51 AM | legaldesire.comL

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up After Analyst Upgrade

September 22 at 10:19 AM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating

September 22 at 7:29 AM | marketbeat.com

Telix Pharmaceuticals Limited (TLX) M&A Call Transcript

September 22 at 7:00 AM | seekingalpha.com

Is Telix's Isotope Takeover Behind Its Share Slide (ASX:TLX)?

September 22 at 5:51 AM | kalkinemedia.comK

ASX Preview: Australian Shares to Rise as Oil Prices Retreat; Telix Pharmaceuticals Receives ASX Waivers on Share Issuance Timing for Acquisition Consideration

September 21 at 10:53 PM | au.finance.yahoo.com

What is this broker's view on Telix shares after yesterday's crash?

September 21 at 10:53 PM | msn.com

Telix and ITM merge to create a radiopharmaceutical powerhouse

September 21 at 5:52 PM | thepharmaletter.comT

Telix Pharmaceuticals Shares Down Double Digits: Here’s Why

September 21 at 5:52 PM | thebull.com.auT

Telix Pharmaceuticals Limited agreed to acquire ITM Isotope Technologies Munich SE for $2.3 billion .

September 21 at 12:51 PM | marketscreener.comM

Telix Stock Drops 10% Following ITM Isotope Merger Deal

September 21 at 12:51 PM | rttnews.com

Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion

September 21 at 12:51 PM | finance.yahoo.com

Telix beefs up radioisotopes supply with $2.35 billion deal; shares crash

September 21 at 12:51 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, RLAY, CELC, and TLX Company Descriptions

Adlai Nortye NASDAQ:ANL

$15.75 -0.85 (-5.12%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$15.65 -0.10 (-0.63%)

As of 09/23/2026 07:30 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Celcuity NASDAQ:CELC

$79.99 -4.11 (-4.89%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$80.16 +0.17 (+0.21%)

As of 09/23/2026 07:30 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Relay Therapeutics NASDAQ:RLAY

$18.03 -1.32 (-6.82%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$18.41 +0.38 (+2.11%)

As of 09/23/2026 07:56 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$11.27 -0.68 (-5.69%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$11.70 +0.43 (+3.81%)

As of 09/23/2026 07:59 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, RLAY, CELC, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, RLAY, CELC, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, RLAY, CELC, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, RLAY, CELC, and TLX Company Descriptions

Adlai Nortye NASDAQ:ANL

Celcuity NASDAQ:CELC

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, RLAY, CELC, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, RLAY, CELC, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, RLAY, CELC, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, RLAY, CELC, and TLX Company Descriptions

Adlai Nortye NASDAQ:ANL

Celcuity NASDAQ:CELC

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools